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• On average, aortic stiffness increases on continuous-flow left ventricular assist device 
(CF-LVAD) therapy. 
• However, aortic stiffness does not increase in all patients on CF-LVAD therapy. 
• LVAD patients who had an increased aortic stiffness had an increased risk of the 




In parallel with the major advances in clinical care, technological advancements and 
implantation of mechanical circulatory support in patients with severe heart failure have 
resulted in these patients living longer. However, these patients are still at risk of increased risk 
of stroke and gastrointestinal bleeding. The unique continuous non-pulsatile flow produced by 
various left ventricular assist devices (LVAD) has been suggested as one potential reason for 
this increased risk of stroke and GI bleeding. Furthermore, these non-pulsatile devices 
challenge our understanding of circulatory blood pressure and flow regulation in relation to 
organ health. In healthy pulsatile and dynamic systems, arterial stiffness is a major independent 
risk factor for stroke. However, to date, there are limited data regarding the impact of LVAD 
therapy on arterial stiffness. The purpose of this report is to discuss the varied impact of LVAD 
therapy on arterial stiffness and attempt to highlight some potential mechanisms linking these 




Major advancements in mechanical circulatory support mean that patients suffering severe 
heart failure are now living longer as a result Left Ventricular Assist Devices (LVAD) therapy 
(Colombo et al., 2018; Mehra et al., 2018; Mehra et al., 2019). However, in parallel with these 
important improvements in outcome, patients implanted with LVADs continue to be at 
increased risk of peripheral organ damage, including stroke and gastrointestinal (GI) bleeding 
(Colombo et al., 2019). As already detailed in “Bionic Women and Men part 1” (Stöhr et al., 
2020), this increased risk of stroke and GI bleeding in LVAD patients may be associated with 
the non-pulsatile nature of the continuous flow and its impact on blood flow dynamics, blood 
pressure regulation and overall organ health (Stöhr et al., 2019a, b). In non LVAD patients, 
flow dynamics, blood pressure regulation and organ health are all in some way associated with 
changes in arterial stiffness, with increased stiffness being associated with increased 
cardiovascular (CV) risk (Ben-Shlomo et al., 2014). The purpose of this report will be to 
highlight and discuss the varied impact of LVAD therapy on arterial stiffness and attempt to 
highlight some potential mechanisms linking these associations in this unique population. 
Continuous Flow and Arterial Stiffness 
Increased large artery stiffness as measured by aortic pulse wave velocity is independently 
associated with an increased risk of stroke and cardiovascular disease (Ben-Shlomo et al., 
2014). However, these data are derived from circulatory systems with dynamic oscillations, 
whereby one can measure the influence of blood pressure and the relative deformation of the 
artery and pulse wave velocities to measure stiffness.  
To date, there are no literature describing the assessment of artery stiffness during LVAD 
therapy due to the inability to measure artery deformation and pulse wave velocities of these 
non-pulsatile and continuous-flow systems. However, a number of studies have attempted to 
understand the impact of LVAD therapy on arterial stiffness by assessing the stiffness before 
patients are implanted with an LVAD and subsequently after the patient has been taken off the 
LVAD and has received a heart transplant. The first study to show the changes in aortic 
stiffness was conducted by Ambardekar and colleagues in 2015, who showed a significant 
increase in aortic stiffness index of tissue samples harvested before LVAD implantation and 
after orthotopic heart transplant (Ambardekar et al., 2015). Interestingly, this study provided 
an important insight into the arterial morphological structural changes (significant reductions 
in elastin and significant increases in collagen) in the aortic tissue in those implanted with an 
LVAD compared to heart failure and healthy controls. Furthermore, in 2017, the same group 
showed that non-invasive echocardiographic measures of aortic stiffness index confirmed an 
increased stiffness in LVAD patients in vivo and that the change in stiffness was determined 
by whether or not the LVAD had a pulse or not (Patel et al., 2017). However, these observations 
did not determine whether the LVAD with a pulse was directly related to the device, the hearts 
ability to impact on the pulse produced or the speed settings of the devices implanted.  
More recently, our own data showed that on average, aortic stiffness did increase whilst on 
LVAD therapy. However, aortic stiffness did not increase in all patients, and those patients 
with increased aortic stiffness had the highest risk of composite outcome of stroke, GI bleeding 
and pump thrombosis. Interestingly, those individuals with increased aortic stiffness were on 
LVAD therapy for a longer duration and were on lower numbers of ACE inhibitors or ARBs 
compared to those that had an unaltered or decreased aortic stiffness (Rosenblum et al., 2018).  
Paradoxically, patients who had an increased stiffness with LVAD therapy had a significantly 
lower baseline stiffness, suggesting that prior stiffness may reduce the risk during subsequent 
LVAD therapy. Further work is required to understand the mechanisms associated with the 
progression of aortic stiffness in various pulsatile and non-pulsatile CF-LVAD patient groups, 
especially with the introduction of the 3rd generation LVAD devices that have an added 
‘artificial pulse’ (HM3 and HVAD LVADs).  
Potential Mechanisms 
As already eluded to in the communications report “Bionic Women and Men Part 1” (Stöhr et 
al., 2020), the role of pulsatility has been a topic of great debate in terms outcome in LVAD 
patients. In a healthy, non-LVAD, dynamic system, the cyclical changes in blood flow and 
pressures produce optimal shear and interaction with the endothelial cells lining the walls of 
the arteries that elicits the release of nitric oxide (NO) required for smooth muscle relaxation 
and dilation. If, in an LVAD system, the output does not produce sufficient mechanical 
dynamics stress and shear on the intima of the arterial wall, the endothelium may not produce 
sufficient NO to maintain macro- and microvascular health (Nakano et al., 2000). However, 
one could argue that because of the low arterial stretch due to the low pulsatile flows and 
pressures, reduced endothelial derived NO production may become the normal state for LVAD 
patients under stable circumstances, but could be contributing to the increased risk due to a 
blunted vascular reactivity in situations when regulation of pressures and flow are required. 
Importantly, it is proposed that the role of endothelial derived NO in a dynamic system is 
associated with endothelial function (Moncada et al., 1988). Interestingly, endothelial function 
as measured by flow mediated dilation (FMD) has been shown to be impaired in LVAD 
patients (Witman et al., 2015). As endothelial dysfunction is considered one mechanism related 
to increased large artery stiffening (McEniery et al., 2006), it is acceptable to propose that this 
link may be one that plays a fundamental role in the LVAD and arterial stiffness story. Whether 
the settings and the degree of pulsatile flow and pressure outputs from different LVADs, in 
different patients, has a role to play in endothelial production of NO, endothelial dysfunction 
and development of arterial stiffness remains to be seen. Better description of macro- and 
microvascular flow and pressure profiling (haemodynamic profiling) in LVAD patients are 
needed to better inform and understand individual CV risk in the future. 
In addition to the relationship between continuous flow associated with LVAD therapy and 
endothelial function, it has been proposed that the lack of pressure and flow oscillations in CF-
LVAD therapy significantly affects baroreceptor sensitivity and function in regulating BP in 
LVAD patients. It has been shown that the degree of pulsatility or having some pulsatility in 
the LVAD impacts on sympathetic activity (SA) (Cornwell et al., 2015). In addition, authors 
of the same paper have previously investigated the impact of acute alterations in the LVAD 
settings and subsequent flow outputs from LVAD therapy in relation to sympathetic activity. 
These data demonstrated that an acute increase in LVAD speed is associated with increased 
SA. Through increasing speed, the pulsatile nature of the flow and output is diminished enough 
to unload the baroreceptors and in turn increases SA. Importantly, increased SA has been 
shown to relate to arterial remodelling and increase arterial wall thickness (Dinenno et al., 
2000)  in dynamic systems. Therefore, the impact of speed and settings of LVAD therapy on 
individual flow and pressure outputs may directly impact the SA of patients and have long term 
vascular structural and functional implications that may impact on future CV risk. Similar to 
the impact of reducing endothelial function when on LVAD therapy, increased arterial wall 
thickness and stiffness will consequently disable the buffering capabilities of the large arteries 
(when needed) and potentially expose the microcirculation to detrimental pulsatile energy in a 
system ill prepared to deal with such oscillations (Stöhr et al., 2018). 
The cumulative effect of LVAD therapy on functional and structural mechanisms of arterial 
stiffness may significantly impact on the individual patient’s CV risk. Importantly, our group 
have previously shown that systolic BP in CF-LVAD patients is relatively low compared to 
healthy people when measured in the office setting, however, for the first time, use of 24-hour 
monitoring has shown that these patients can present with multiple hypertensive crises over 24 
hours. Therefore, in LVAD patients sensitive to minimal increases in BP, increased large artery 
stiffness and an inability to buffer pressure and flow when needed, presenting with multiple 
hypertensive episodes over 24-hours may significantly increase the patients’ risk of stroke and 
GI bleeds. 
Future Perspectives 
Moving forward, it is critical that clinicians and scientists work together to develop a clear 
understanding of how the unique haemodynamics of traditional LVADs and third-generation 
LVADs impact patients in relation to their increased risk of stroke and GI bleeding. 
Longitudinal data are needed to investigate the contributing factors associated with changes in 
large artery stiffness in CF-LVAD patients and, furthermore, detailed descriptions of these 
changes are needed in parallel with microvascular flow dynamics in order to accurately and 
holistically understand the haemodynamics to inform treatment of LVAD patients in the future.  
Links to further material 
The “HIT-LVAD” project material can be accessed on link: ResearchGate website. 
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